改良及高敏改良格拉斯哥预后评分在下咽鳞状细胞癌中的应用价值
Utility of the Modified and High-Sensitivity Modified Glasgow Prognostic Scores for Hypopharyngeal Squamous Cell Carcinoma.
作者信息
Iuchi Hiroyuki, Ohori Junichiro, Matsuzaki Hisahiro, Kiyama Satoshi, Yamashita Masaru
机构信息
Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
出版信息
OTO Open. 2021 Dec 15;5(4):2473974X211067423. doi: 10.1177/2473974X211067423. eCollection 2021 Oct-Dec.
OBJECTIVE
To determine whether the modified Glasgow prognostic score (mGPS) and high-sensitivity mGPS (HS-mGPS) could predict outcomes among patients with hypopharyngeal squamous cell carcinoma (HSCC).
STUDY DESIGN
Retrospective cohort study.
SETTING
Affiliated university hospital.
METHODS
We reviewed the records of 115 patients with histologically confirmed HSCC between March 2007 and December 2019. Univariate and multivariable Cox proportional hazard analyses were performed for overall survival (OS) and disease-free survival (DFS).
RESULTS
The 5-year OS rates were 84.0% for the mGPS0 group, 47.8% for the mGPS1 group, and 17.9% for the mGPS2 group ( < .0001), while the 5-year OS rates were 86.7% for the HS-mGPS0 group, 69.0% for the HS-mGPS1 group, and 22.2% for the HS-mGPS2 group ( < .001). The mGPS and HS-mGPS were both associated with OS in the univariate analyses, although only the HS-mGPS was independently associated with OS (hazard ratio, 2.68 [95% CI, 1.19-6.05]; < .05). The 5-year DFS rates were 75.8% for the mGPS0 group, 53.0% for the mGPS1 group, and 13.8% for the mGPS2 group ( < .001), while the 5-year DFS rates were 79.8% for the HS-mGPS0 group, 56.8% for the HS-mGPS1 group, and 11.6% for the HS-mGPS2 group ( < .001). The mGPS and HS-mGPS were both associated with DFS in the univariate analyses, although only the HS-mGPS was independently associated with DFS (hazard ratio, 2.35 [95% CI, 1.03-5.37]; < .05).
CONCLUSION
Our study suggests that the HS-mGPS is useful as prognostic factor in HSCC.
目的
确定改良格拉斯哥预后评分（mGPS）和高敏mGPS（HS-mGPS）能否预测下咽鳞状细胞癌（HSCC）患者的预后。
研究设计
回顾性队列研究。
研究地点
大学附属医院。
方法
我们回顾了2007年3月至2019年12月期间115例经组织学确诊的HSCC患者的记录。对总生存期（OS）和无病生存期（DFS）进行单因素和多因素Cox比例风险分析。
结果
mGPS0组的5年OS率为84.0%，mGPS1组为47.8%，mGPS2组为17.9%（P<0.0001），而HS-mGPS0组的5年OS率为86.7%，HS-mGPS1组为69.0%，HS-mGPS2组为22.2%（P<0.001）。在单因素分析中，mGPS和HS-mGPS均与OS相关，尽管只有HS-mGPS与OS独立相关（风险比，2.68[95%CI，1.19-6.05]；P<0.05）。mGPS0组的5年DFS率为75.8%，mGPS1组为53.0%，mGPS2组为13.8%（P<0.001），而HS-mGPS0组的5年DFS率为79.8%，HS-mGPS1组为56.8%，HS-mGPS2组为11.6%（P<0.001）。在单因素分析中，mGPS和HS-mGPS均与DFS相关，尽管只有HS-mGPS与DFS独立相关（风险比，2.35[95%CI，1.03-5.37]；P<0.05）。
结论
我们的研究表明，HS-mGPS可作为HSCC的预后因素。
Zotero 插件